1. Introduction {#sec1}
===============

On May 12, 2008, an earthquake measuring 8.0 on the Richter scale hit Sichuan Province in southwestern China. According to the official data, more than 69,200 people were confirmed dead, more than 374,600 were seriously injured \[[@B1]\], and at least 5 million were left homeless \[[@B2]\]. Recent literature shows that posttraumatic stress disorder (PTSD) and other psychological disorders such as anxiety and depression were fairly common and highly comorbid in 2008 Sichuan earthquake survivors \[[@B3]\].

Posttraumatic stress disorder (PTSD) is a significant public health problem \[[@B4]\]. About 6.8% of adults develop PTSD in their lifetimes; 3.5% have the condition in any given year \[[@B5], [@B6]\]. Approximately 10%--50% of the survivors of traumatic events such as earthquakes and tsunamis will develop chronic PTSD \[[@B7]\], which often persists for years if untreated \[[@B8]--[@B10]\]. The disorder is characterized by flashbacks and avoidance or numbness as well as hyperarousal after experiencing, witnessing, or confronting actual or potential death, serious physical injury, or a threat to physical integrity \[[@B11]\]. In addition to these symptoms, co-morbid psychiatric disorders are extremely common. In the National Comorbidity Survey (USA), approximately 80% of individuals with PTSD also met criteria for at least one other disorder listed in the diagnostic and statistical manual of mental disorders-III (DSM-III) \[[@B4]\]. Patients with PTSD often manifest other complications such as depression, anxiety, obsessive-compulsive behavior, hostility, and paranoid ideation disorders \[[@B3], [@B12]--[@B16]\]. Co-morbid psychiatric disorders and related subclinical symptoms combined with core PTSD symptoms result in poor general psychological status (GPS).

Selective serotonin reuptake inhibitors are the usual first level pharmacological treatment for PTSD \[[@B17]--[@B22]\]. Other lines of drugs, such as benzodiazepines and monoamine oxidase inhibitors, are also commonly used \[[@B23]\]. However, the effects of these pharmaceuticals are not always satisfactory \[[@B23]--[@B25]\], and undesirable side effects such as sleep disturbance, sexual dysfunction, and dizziness have been reported \[[@B23], [@B26]--[@B29]\].

For centuries, traditional Chinese medicine (TCM) has been widely used in China and some other Asian countries for psychological disorders, and many classic herbal formulas have been used to treat such maladies \[[@B30]--[@B38]\]. *Xiao-Yao-San* is one of the most popular \[[@B30]--[@B36]\]. We developed a modified, granulated form of *Xiao-Yao-San, Xiao-Tan-Jie-Yu-Fang* (XTJYF), by adding additional herbs, mainly from another classic TCM formula*Er-Chen-Tang* for treating depression, and we studied the safety and effects of this modification in cancer patients with depression (see [Table 1](#tab1){ref-type="table"}) \[[@B39]\]. Because we found the formula effective and observed no serious side effects, we hypothesized that XTJYF would improve GPS in PTSD patients.

2. Subjects and Methods {#sec2}
=======================

2.1. Study Design and Setting {#sec2.1}
-----------------------------

Patients were enrolled into this study five months after the 2008 Sichuan earthquake, between October 2008 and January 2009, through a community-based epidemiological survey of four settlements of a severely affected city, Dujiangyan. In the enrollment survey, the relationship between exposure to the earthquake and PTSD was assessed. Preliminary screening was performed in the communities by our researchers according to the DSM III for PTSD, Chinese version \[[@B40]\]. Eligible subjects were invited to participate in a diagnostic face-to-face or telephone interview with one of three experienced psychiatrists, each of which has at least eight years of clinical experience. Patients who met the inclusion and exclusion criteria were enrolled (see Patient Flow Chart, [Figure 1](#fig1){ref-type="fig"}), and our psychologists verified PTSD as the primary diagnosis of each enrollee. Inclusion criteria were age 16 or older, meeting DSM III criteria for PTSD with at least one of the nine Symptom Check-List-90-Revised (SCL-90-R) \[[@B41]\] subscores above the Chinese norm \[[@B42]\], and being willing to be randomly assigned. Participants understood that those randomized into the placebo control group could receive XTJYF after completion of the whole trial if they wished. Exclusion criteria were past history of bipolarism, schizophrenia, or other psychotic disorders; current organic mental disorder, factitious disorder, or malingering; any past history of alcohol or substance dependence or abuse; evidence of clinically significant hepatic or renal disease or any other acute or unstable medical condition that might interfere with safe participation in the study; use of any medication with clinically significant psychotropic activity within two weeks of randomization; any cognitive-behavioral therapy during the trial; psychotherapy initiated or ending during the trial. For female patients of childbearing age, participation was contingent on a negative serum pregnancy test and a medically accepted method of contraception.

Written informed consent was obtained from all patients before participation. Patients were free to withdraw from the study at any time. Clinical diagnoses, physicals, and laboratory examinations were mainly conducted in the outpatient clinic at the Air Force Sanatorium in the city of Dujiangyan by our psychologist and other investigators. The research staff collected patients\' weekly feedback on their medical conditions and delivered the XTJYF or placebo through in-house visits. The trial protocol was approved by the Ethics Committee of Shanghai Changzheng Hospital and the Air Force Sanatorium in Dujiangyan.

A sociodemographic inventory and a medical history were taken, and a routine physical and laboratory examination (i.e., blood pressure, ECG, clinical chemistry and hematology tests, and urinalysis) was performed by the investigators as a baseline for future toxicology screening.

2.2. Randomization and Blinding {#sec2.2}
-------------------------------

Eligible patients were randomized to either XTJYF treatment or placebo control. Random numbers were generated by computer software; treatment codes were held by the chief investigator, who was isolated from patients and outcome data. The chief investigator was also responsible for distributing the XTJYF and placebo with the assistance of our research staff. Patients, research staff, and data entry clerks were blinded to treatment group assignment. Treatment compliance was assessed by package count and observation by the research staff. Treatment codes were disclosed after the entire study was completed.

2.3. Study Interventions {#sec2.3}
------------------------

All patients received 12 g packages of granulated XTJYF or placebo twice a day for eight weeks \[[@B39]\] and were instructed to drink the contents dissolved in warm, boiled water.

2.4. Outcome Measures {#sec2.4}
---------------------

Each patient completed the SCL-90-R questionnaires twice, at baseline prior to randomization and in the eighth week after the randomization, that is, at the end of this clinical trial. The SCL-90-R is a questionnaire for self-reporting psychological distress. It is widely used in patients suffering from mental diseases and for psychological evaluation of healthy individuals. The instrument is well accepted for its good internal consistency, dimensional structure, reliability, and validity \[[@B43]--[@B45]\]. The Chinese SCL-90, translated and validated by Wang from the English version of the SCL-90-R, was used \[[@B46], [@B47]\].

The SCL-90-R consists of 90 symptoms of distress. Patients were instructed to indicate the degree to which they had been troubled by each symptom during the preceding week by ranking the symptom from 0 to 4, with 0 being "not at all" and 4 being "extremely." The statements were classified into nine dimensions, or factors (F), that reflect various types of psychopathology: (F1) somatization, (F2) obsessive-compulsive behavior, (F3) interpersonal sensitivity, (F4) depression, (F5) anxiety, (F6) hostility, (F7) phobic anxiety, (F8) paranoid ideation, and (F9) psychoticism. Three supplementary global indices reflect the degree of symptomatology. The global severity index (GSI) registers the average depth of impairment based on the severity recorded for each symptom; the positive symptom total index (PST) indicates the total number of symptoms experienced; the Positive Symptom Distress Index (PSDI) reflects the level of distress by correlating the reported symptoms \[[@B41]\]. In addition, on the SCL-90-R, there are seven items not included in any of the nine factors, among which, three reflect sleep quality. Individual SCL-90-R factors have been used to evaluate the psychological condition of PTSD patients, and there is sufficient evidence to support the correlation of higher global SCL-90-R scores with the severity of a patient\'s core PTSD symptoms \[[@B12], [@B48]--[@B57]\].

During the trial, patients were closely monitored for adverse events (AEs) and worsening of symptoms. The time of onset of any observed or spontaneously reported AE, its duration and severity, any action taken, and the outcome were recorded.

2.5. Herbal Preparation and Dispensing {#sec2.5}
--------------------------------------

The original formula, *Xiao-Yao-San,* contains eight herbs: *Chai-Hu* (*Radix Bupleuri*), *Dang-Gui* (*Radix Angelicae sinensis*), *Fu-Ling* (*Poria*), *Bai-Zhu* (*Rhizoma Atractylodis macrocephalae*), *Bai-Shao* (*Radix Paeoniae alba*), *Bo-He* (*Herba Menthae*), *Zhi Gan-Cao*(*Radix Glycyrrhizae preparata*), and *Sheng-Jiang* (*Rhizoma Zingiberis recens*). Our modification, XTJYF, contains all the herbs of the original formula, except *Sheng-Jiang,* plus additional seven herbs, including *Fa Ban-Xia* (*Rhizoma Pinelliae preparatae*) and *Chen-Pi* (*Pericarpium Citri reticulatae*), that are commonly used for psychological disorders (see [Table 1](#tab1){ref-type="table"}).

All herbal substances used in this trial are listed with the Pharmacopoeia Commission of China, 2005, and are accepted as suitable for human consumption when administered within standard dosage levels. None of these herbs is a controlled substance or an endangered species. Raw herbs were purchased from the Lei Yun Shang Pharmaceutical Company (Shanghai, China). The herbs were extracted with water, and the resulting granules were packaged by the Chinese Drug Preparation Department of Shanghai Changzheng Hospital. Levels of heavy metals and microbial and pesticide residues were carefully assessed, and all fell well within the normal range \[[@B58]\].

The placebo granules, purchased from Jiangsu Tianjiang Pharmaceutical Company, Ltd., were designed to resemble the XTJYF granules in taste, smell, and appearance. The placebo was composed of dextrin, sunset yellow fcf, and a sweetener; the proportion was 1200 : 1 : 7. After being tested on five independent volunteers, the placebo was deemed indistinguishable from XTJYF. XTJYF and the placebo were dispensed in identical opaque packages.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Quantitative data was summarized using mean, standard deviation (SD), or 95% confidence interval (95% CI). Qualitative data was described using proportion, as percentages. Baseline characteristics of the two groups were compared using the two-sided chi-square test or *t*-test at a significance level of 0.05.

Since this was a randomized, blind clinical trial, the statistical analyses for treatment effect evaluation of the primary and secondary outcomes are relatively straightforward. Baseline-to-end-point score changes in the three global SCL-90-R indices and rates of response in the GSI were computed as the primary endpoints. For defining rate of response, patients with a reduction of at least 30% from the baseline GSI score were classified as "much improved"; at least 50%, as "very much improved." Subanalyses of the baseline-to-end-point score changes of the nine SCL factors and sleep quality score (the average of the scores of the three SCl-90-R items on sleep quality) were secondary endpoints. Statistical analysis on both primary and secondary outcomes was done using intention-to-treat analysis (ITT) with statistical software SPSS. Missing values in the SCL-90-R questionnaire for the patients who withdrew from the study before the eighth week were imputed using the last-observation-carried-forward method. For primary outcomes, effect sizes (for three global indices) and number needed to treat (NNT, for rate of response in the GSI), as well as the *P* values from two sample *t*-tests and chi-square tests, are reported in the treatment effect assessment. The same analytic approaches were applied to the secondary outcomes. Additionally, Fisher\'s exact test was used to compare the difference in dropout rate and AEs between the two treatment groups.

3. Results {#sec3}
==========

A total of 3478 individuals were screened, of whom 820 passed the preliminary screening and 245 were finally enrolled into the study; 575 were excluded. Of these, 372 were lost to follow-up or refused enrollment; 178 did not meet the inclusion criteria; 25 met the exclusion criteria. Enrolled patients were randomly assigned to XTJYF (*n* = 123) or placebo (*n* = 122) treatment. Of these, 102 (83%) of the XTJYF group and 99 (81%) of the control group completed the whole study. Reasons for withdrawal from the study are listed separately for each treatment group in [Figure 1](#fig1){ref-type="fig"}, and a detailed discussion on treatment tolerability is provided in [Section 3.4](#sec3.4){ref-type="sec"}.

3.1. Baseline Characteristics and GPS Assessment {#sec3.1}
------------------------------------------------

[Table 2](#tab2){ref-type="table"} shows that randomization was effective and that there were no significant differences between the two groups in baseline demographics, core clinical PTSD symptoms, or baseline SCL-90-R global indices. Even though individual SCL-90-R factor scores and sleep quality scores at baseline are not shown here, we checked all of them and founded no significant differences between the two groups. Notice that women constituted 72% of XTJYF-treated and 71% of placebo-treated patients. Ages ranged from 16 to 85; 64% were over 45.

[Table 3](#tab3){ref-type="table"} shows the urgency of the public health needs of these earthquake-affected PTSD patients and indicates that baseline scores of the patients in our clinical trial are significantly higher in all nine SCL-90-R factors and all three supplementary global indices than those seen in Chinese and American norms \[[@B41], [@B42]\].

3.2. Treatment Effect on Primary Outcomes {#sec3.2}
-----------------------------------------

[Table 4](#tab4){ref-type="table"} shows that patients in the XTJYF group experienced statistically significant improvement after treatment in all three supplementary global index scores compared to the placebo group. Based on the reported effect sizes, XTJYF treatment has a moderate effect on GSI and PSDI indices and a small effect on the PST index. Our findings on the rate of response, defined based on GSI score improvement, are displayed in [Figure 2](#fig2){ref-type="fig"}; 50% of the XTJYF patients versus 28% of those in the placebo group were "much improved," providing statistically significant evidence supporting the advantage of XTJYF over placebo at the level of 0.05 (*P* value = 0.001). The NNT is 4.55. Additionally, as [Figure 2](#fig2){ref-type="fig"} shows, 20% of the XTJYF patients versus 12% of those in the placebo group were "very much improved," but this result is not statistically significant (*P* value = 0.12).

3.3. Treatment Effect on Secondary Outcomes {#sec3.3}
-------------------------------------------

The second part of [Table 4](#tab4){ref-type="table"} displays the treatment effects of XTJYF and placebo on the nine SCL factors and sleep quality score. The results indicate that, in comparison to placebo, the XTJYF group experienced statistically significant improvement after treatment in five of the nine SCL factors, somatization (*P* = 0.003), obsessive-compulsive behavior (*P* = 0.036), depression (*P* = 0.001), anxiety (*P* \< 0.001), and hostility (*P* = 0.019). Based on the reported effect sizes, XTJYF treatment has a moderate effect on somatization, depression, anxiety, and hostility, as well as a small effect on obsessive-compulsive behavior, interpersonal sensitivity, and phobic anxiety. [Table 4](#tab4){ref-type="table"} also shows that XTJYF treatment yielded statistically significant improvement in sleep quality at the end of the study, with a *P* value of less than 0.001 and a moderate effect size.

3.4. Treatment Tolerability {#sec3.4}
---------------------------

Overall, XTJYF was well tolerated. Compliance rate, 83% for the XTJYF and 81% for the placebo group, was reasonably high. Six in the XTJYF and five in the control group withdrew due to adverse effects, so reported AEs were similar in the two groups. The most frequently reported AEs were nausea (14.6% versus 9.0%; *P* = 0.24), diarrhea (10.6% versus 6.5%; *P* = 0.36), and malaise (10.6% versus 12.3%; *P* = 0.69). All AEs were minor and were determined to be unrelated to the ingestion of XTJYF. In the XTJYF group, 21 subjects dropped out (17.1%); in the placebo group, 23 did (18.9%, *P* = 0.74). The primary reasons cited for dropout in the XTJYF and placebo groups, respectively, were AE (4.9% versus 4.1%; *P* = 1); lost to follow-up (1.6% versus 2.5%; *P* = 0.68); protocol violation (4.9% versus 3.3%; *P* = 0.75); lack of efficacy (3.3% versus 6.6%; *P* = 0.25); miscellaneous reasons, for example, disliked the taste of the herbs (2.4% versus 2.5%; *P* = 1). Subjects\' laboratory values and vital signs were similar in the two groups. Changes in these values were minor, infrequent, and not considered clinically meaningful.

4. Discussion {#sec4}
=============

In the present study, we compared our data to the Chinese norm calculated by Jin et al. \[[@B42]\] and to the USA norm published by Derogatis \[[@B41]\]. (see [Table 3](#tab3){ref-type="table"}). At baseline, the nine SCL factors and three global indices were higher than the norm in these earthquake-related PTSD subjects, suggesting that earthquake-related PTSD is accompanied by poor GPS. These findings are consistent with those reported by other investigators \[[@B3], [@B59]--[@B63]\].

Hypothesizing that it would improve poor GPS in earthquake-related PTSD, we investigated a Chinese herbal formula, XTJYF, modified from a classic formula, *Xiao-Yao-San*, and found that, compared to placebo, XTJYF significantly improved all of the three global indices of SCl-90-R, and a significantly greater proportion of patients were "much improved" according to changes in GSI score. (See [Table 4](#tab4){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). A subanalysis provided a more detailed look at specific XTJYF effects on poor GPS, showing that five of the nine SCL factors and sleep quality score improved. (see [Table 4](#tab4){ref-type="table"}).

These findings suggest that XTJYF may globally improve GPS in earthquake-related PTSD patients, specifically in somatization, obsessive-compulsive behavior, depression, anxiety, and hostility. In addition, the formula may improve the sleep quality of the patients and appears to be safe. Although a few subjects reported gastrointestinal complaints such as nausea and diarrhea during treatment, these were probably due to the poor diet available after the earthquake; these symptoms were also frequently reported in the placebo control group. Our findings are consistent with those of our previous study on XTJYF for cancer patients with depression \[[@B39]\].

The results are meaningful because all five of the psychological disorders mentioned above are associated with high levels of functional and psychosocial disability in chronic PTSD patients \[[@B3], [@B4], [@B6], [@B12]--[@B16], [@B64]--[@B69]\], and most are reported to predict greater refractoriness to routine therapy in individuals diagnosed with PTSD \[[@B17], [@B70]--[@B73]\]. For example, PTSD patients who report somatic symptoms also report higher overall PTSD symptoms \[[@B15], [@B64]\] and a higher frequency of depression \[[@B64], [@B74]\]. Patients with co-morbid PTSD and obsessive-compulsive behavior have been found to have a poorer response to cognitive behavioral therapy than those diagnosed with PTSD alone \[[@B73]\]. Co-morbid PTSD/depression appears to predict greater refractoriness to pharmacotherapy, greater symptom severity, lower levels of functioning and rates of recovery, and increased disability and potential of suicide \[[@B4], [@B6], [@B65]--[@B67]\]. Like depression, anxiety symptoms are associated with lower quality-of-life estimates and greater refractoriness to routine pharmacotherapy in PTSD patients \[[@B3], [@B68]\]. Hostility, which according to a meta-analysis of 39 studies is significantly elevated in individuals with PTSD \[[@B16]\], is linked to adverse health outcomes, including cardiac death \[[@B69]\]. In the present study, XTJYF also appears to improve the sleep quality of these PTSD patients; sleep disturbances are among the most treatment-resistant symptoms of PTSD \[[@B75]\]. All of these symptoms are likely to contribute to alcohol and drug abuse \[[@B76], [@B77]\] as well as suicidal ideation \[[@B78]\].

The psychological mechanisms of action of *Xiao-Yao-San* and its modifications have been investigated. It has been reported that the formula may act on psychological symptoms by upregulating central neurotransmitters such as serotonin. Bao et al. \[[@B79]\] reported that *Xiao-Yao-San* produced antidepressant effects in a mouse model of depression by ameliorating brain cortex 5-HT and 5-HIAA content. Other mechanisms of the formula have also been reported. Yue et al. \[[@B80]\] reported that *Xiao-Yao-San*suppressed chronic stress in a rat model by up-regulating GluR2/3, the AMPA receptor subunit 2/3, which mediates the postsynaptic depolarization that initiates neuronal firing \[[@B81]\], and by downregulating PICK1, a protein that interacts with C-kinase 1, which may lead to AMPA receptor anchorage \[[@B82]\] in hippocampal regions CA1 and CA3. Similar findings, that *Xiao-Yao-San* upregulates AMPA receptor subunit mRNA expression in hippocampal region CA1 and the amygdala, were reported \[[@B83]\]. Furthermore, *Xiao-Yao-San*and its modifications were reported to suppress chronic stress by maintaining the stability of hippocampal neurons \[[@B84]\], inhibiting hypothalamic-pituitary-adrenocortical axis negative feedback regulation \[[@B85]\], and counteracting increase of Ca^2+^ concentration in hippocampal synaptosomes \[[@B86]\]. Based on TCM theory, seven drugs were added in our modification, mainly from another classic TCM formula, *Er-Chen-Tang*. According to our previous preclinical study, this modification may suppress depression by up-regulating the 5-HT~1A~ receptor in the hippocampus in a rat model of chronic stress \[[@B87]\]. However, because *Xiao-Yao-San* and its modifications contain multiple ingredients, specific active ingredients have not been identified, and the herbal interactions within the formula have not been systematically investigated. Further investigation to elucidate the mechanisms of action of this formula is warranted.

Several limitations to this study should be noted. First, our trial lacked a long follow-up assessment. This was largely due to the difficulties in following up this particular population, which consisted of earthquake survivors living in shelters with no specific address. In the patient recruitment stage, more than 45% (372 of 820) of those preliminarily screened for PTSD were lost to follow-up. Secondly, we did not include a questionnaire measuring specific PTSD core symptoms, mainly because of the low level of education in this mountain population. In our patient population, 43% had an elementary education or less and found it difficult to complete a single 90-question SCL-90-R questionnaire. However, although we did not include a specific questionnaire such as the Clinician-Administered PTSD Scale \[[@B88]\] or the Clinician-Rated Treatment Outcome PTSD Scale \[[@B89]\] to measure core PTSD symptoms, the widely used SCL-90-R captures a broader patient psychological profile than a specific PTSD questionnaire would do. Thirdly, only one dosage of XTJYF was used in this study, that used in our standard clinical practice. A higher dosage might benefit the nonresponders. Finally, more detailed information on types of trauma and the percentages of patients who suffered them should be gathered and analyzed.

Despite the limitations, our findings provide preliminary support for the use of TCM in treating GPS in earthquake survivors with PTSD. TCM has been used extensively in China to treat people suffering from various diseases after disasters, for it is readily available, reasonably cheap, effective, and safe. Because of their wide usage, the production of TCM herbal products is quick and cost effective in China. Traditional Chinese herbal medicine may provide an adjuvant therapy that is safe, effective, and timely for affected populations in natural disasters such as earthquakes.
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###### 

Ingredients of Xiao-Tan-Jie-Yu-Fang.

  No.      Chinese name    Pharmaceutical name                             Proportion, %
  -------- --------------- ----------------------------------------------- ---------------
  \(1\)    Chai-Hu         *Radix Bupleuri*                                4.5
  \(2\)    Dang-Gui        *Radix Angelicae sinensis*                      4.5
  \(3\)    Fu-Ling         *Poria*                                         15.2
  \(4\)    Chao Bai-Zhu    *Rhizoma Atractylodis macrocephalae*(parched)   4.5
  \(5\)    Chao Bai-Shao   *Radix Paeonia alba* (parched)                  7.6
  \(6\)    Bo-He           *Herba Menthae*                                 3.0
  \(7\)    Zhi Gan-Cao     *Radix Glycyrrhizae preparatae*                 3.0
  \(8\)    Huang-Lian      *Rhizoma Coptidis*                              1.5
  \(9\)    Fa Ban-Xia      *Rhizoma Pinelliae preparatae*                  7.6
  \(10\)   Chen-Pi         *Pericarpium Citri reticulatae*                 4.5
  \(11\)   Duan Long-Gu    *Os Draconis* (calcined)                        15.0
  \(12\)   Duan Mu-Li      *Concha Ostreae* (calcined)                     15.0
  \(13\)   Zhi Da-Huang    *Radix et Rhizoma Rhei preparatae*              6.1
  \(14\)   Shi-Changpu     *Rhizoma Acori graminei*                        7.6

###### 

Baseline characteristics, earthquake-affected PTSD patient treatment groups.

  -------------------------------------------------------------------------------------------------------------
  Variable                                                                   XTJYF\        Placebo\      *P*
                                                                             (*N*= 123)    (*N* = 122)   
  -------------------------------------------------------------------------- ------------- ------------- ------
  Sex, *n* (%)                                                                                            

   Female                                                                    88 (71.5)     86 (70.5)     0.89

   Male                                                                      35 (28.5)     36 (29.5)     

  Age, mean (SD)                                                             51.2 (15.0)   51.0 (16.0)   0.93

  Marital status, *n* (%)                                                                                 

   Married or living together                                                99 (80.5)     96 (78.7)     0.75

   Others (unmarried, divorced, etc.)                                        24 (19.5)     26 (21.3)     

  Education, *n* (%)                                                                                      

   Primary school or less                                                    51 (41.5)     53 (43.4)     0.80

   More than primary school                                                  72 (58.5)     69 (56.6)     

  Occupation, *n* (%)                                                                                     

   Farmer or unemployed                                                      89 (72.4)     86 (70.5)     0.78

   Other employment or retired                                               34 (27.6)     24 (19.5)     

  Clinical PTSD symptom data, *n* (%)                                                                     

   Uncontrollable recall of earthquake experiences                           81 (65.9)     85 (69.7)     0.59

   Repeated nightmares of earthquake                                         53 (43.1)     54 (44.3)     0.90

   Repeated hallucinations                                                   46 (37.4)     38 (31.1)     0.35

   Heart racing, sweating, pallor when viewing earthquake ruins or victims   91 (74.0)     82 (67.2)     0.26

   Poor sleep                                                                87 (70.7)     86 (70.5)     1.00

   Tense or easily agitated                                                  97 (78.9)     92 (75.4)     0.55

   Lack of concentration                                                     60 (48.8)     50 (41.0)     0.25

   Panic                                                                     52 (42.3)     45 (36.9)     0.43

   Avoids recalling anything related to the earthquake                       73 (59.3)     73 (59.8)     1.00

   Avoids activities related to earthquake                                   56 (45.5)     55 (45.1)     1.00

   Avoids contact with others, indifferent to relatives                      54 (43.9)     45 (36.9)     0.30

   Loss of interest and motivation                                           51 (41.5)     55 (45.1)     0.61

   Selectively forgetful                                                     67 (54.5)     62 (50.8)     0.61

   Loss of hope for the future                                               34 (27.6)     39 (32.0)     0.49

  Lost relatives in the earthquake, *n* (%)                                  7 (5.7)       11 (9.0)      0.34

  Baseline outcome measures from SCL-90-R, mean (SD)                                                      

   Global severity index                                                     1.14 (0.61)   1.12 (0.60)   0.78

   Positive symptom total index                                              48.4 (20.0)   48.8 (18.8)   0.87

   Positive symptom distress index                                           2.14 (0.97)   2.00 (0.52)   0.18
  -------------------------------------------------------------------------------------------------------------

###### 

SCL-90-R Factor scores, Chinese and American norms compared to earthquake-affected PTSD patients at baseline.

  Sample                            Norm, China^*⋆*^    Norm, USA^●^        PTSD, Sichuan
  --------------------------------- ------------------- ------------------- ----------------------
  Somatization                      0.37 (0.34--0.40)   0.36 (0.33--0.39)   1.20 (1.11--1.29)\*
  Obsessive-compulsive behavior     0.62 (0.59--0.65)   0.39 (0.36--0.42)   1.38 (1.29--1.47)\*
  Interpersonal sensitivity         0.65 (0.62--0.68)   0.29 (0.27--0.31)   0.93 (0.84--1.02)\*
  Depression                        0.50 (0.47--0.53)   0.36 (0.33--0.39)   1.29 (1.18--1.39)\*
  Anxiety                           0.39 (0.37--0.41)   0.30 (0.28--0.32)   1.25 (1.15--1.34)\*
  Hostility                         0.46 (0.43--0.49)   0.30 (0.27--0.33)   1.12 (1.02--1.23)\*
  Phobic anxiety                    0.23 (0.21--0.25)   0.13 (0.11--0.15)   0.93 (0.83--1.03)\*
  Paranoid ideation                 0.43 (0.40--0.46)   0.34 (0.31--0.37)   0.74 (0.65--0.83)\*
  Psychoticism                      0.29 (0.27--0.31)   0.14 (0.12--0.16)   0.77 (0.69--0.85)\*
  Global severity index                                 0.31 (0.29--0.33)   1.13 (1.05--1.20)`∆`
  Positive symptom total index      24.9 (24.0--25.9)   19.3 (18.3--20.3)   48.6 (46.2--51.1)\*
  Positive symptom distress index                       1.32 (1.29--1.35)   2.07 (1.97--2.17)^∆^

`⋆`The original data was obtained from Jin et al. \[[@B42]\]. We recalculated the original data from "mean (sd)" to "mean (95% CI)" in order to make these data comparable. ^●^The original data was obtained from Derogatis \[[@B41]\]. We recalculated the original data from "mean (sd)" to "mean (95% CI)" in order to make these data comparable.\*Compared to the Chinese and American norms, *P* \< 0.05. `∆`Compared to the American norms, *P* \< 0.05.

###### 

XTJYF treatment effect on primary and secondary outcomes.^(1)^

  SCL-90-R factor                   XTJYF (*N* = 123)   Placebo (*N* = 122)   Effect size^(2)^   *P* ^(3)^
  --------------------------------- ------------------- --------------------- ------------------ -------------
  *Primary outcomes*                                                                              
  Global severity index             0.30 (0.24--0.37)   0.15 (0.09--0.21)     **0.424**          **0.001**
  Positive symptom total index      6.66 (4.58--8.73)   3.52 (1.62--5.41)     0.284              **0.028**
  Positive symptom distress index   0.38 (0.30--0.45)   0.19 (0.12--0.26)     **0.448**          **0.001**
  *Secondary Outcomes*                                                                            
  Somatization                      0.34 (0.25--0.43)   0.16 (0.08--0.24)     **0.391**          **0.003**
  Obsessive-compulsive behavior     0.28 (0.20--0.36)   0.15 (0.07--0.24)     0.270              **0.036**
  Interpersonal sensitivity         0.27 (0.19--0.35)   0.16 (0.08--0.24)     0.241              0.061
  Depression                        0.35 (0.27--0.44)   0.16 (0.08--0.24)     **0.420**          **0.001**
  Anxiety                           0.40 (0.29--0.50)   0.12 (0.04--0.21)     **0.500**          **\<0.001**
  Hostility                         0.31 (0.21--0.40)   0.15 (0.06--0.24)     **0.304**          **0.019**
  Phobic anxiety                    0.23 (0.14--0.32)   0.13 (0.05--0.21)     0.211              0.101
  Paranoid ideation                 0.16 (0.08--0.24)   0.12 (0.04--0.21)     0.070              0.586
  Psychoticism                      0.19 (0.11--0.26)   0.15 (0.08--0.23)     0.077              0.548
  Sleep quality                     0.76 (0.58--0.94)   0.33 (0.19--0.47)     **0.467**          **\<0.001**

^(1)^Statistical analysis was done using intent-to-treat analysis (ITT) with SPSS. ^(2)^Cohen\'s d effect size measure, in which an effect size of 0.2 to 0.3 is considered a "small" effect, around 0.5, a "medium" effect, and 0.8 to infinity, a "large" effect, is used here. ^(3)^The *P* values come from the two sample *t*-tests.

[^1]: Academic Editor: David Mischoulon
